ArticleCancer research2025
Can't KEEP Up: UXS1 Dependency Exposes a Pyrimidine Vulnerability in KEAP1-Mutant Lung Cancer.
Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss-of-function mutations in KEAP1 are found in more than 20% of non-small cell lung cancers. These mutations stabilize the transcription factor NRF2 to induce a battery of antioxidative and cytoprotective genes. Although NRF2 accumulation promotes cancer cell fitness, it also creates several targetable vulnerabilities. In this issue of Cancer Research, Gebru and colleagues reveal the dependency of KEAP1-mutant non-small cell lung cancers on UDP-xylose synthase 1 (UXS1). The authors found that NRF2-driven expression of UDP-glucose 6-dehydrogenase leads to the accumulation of UDP-glucuronic acid. Consequently, loss of UXS1-mediated UDP-glucuronic acid decarboxylation causes sequestration of UDP, depletion of pyrimidine pools, and replication stress, thereby inducing apoptosis and senescence. Importantly, these effects are selective to KEAP1-mutant tumors, with KEAP1 wild-type cells and normal tissue unaffected by UXS1 loss. DNA damage induction with cell-cycle kinase inhibitors synergized with UXS1 loss to promote the death of KEAP1-mutant cells. These findings suggest that UXS1 loss is synthetic lethal with NRF2 activation and may be a promising target for therapy. See related article by Gebru et al., p. 4806.
Indexed as
Identifiers
41321105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.